PARP1 and cancer: While in ovarian cancer overexpressed lipogenic enzymes are increasingly seen as potential therapeutic opportunity to inhibit cancer growth, peritoneal metastasis and/or overcome resistance to chemotherapy or anti-angiogenic therapy [61, 63, 64], our study is the first demonstration that the combined inhibition of PARP1 and FSAN represents an synergistic anti-proliferative combination strategy.